Advanced Therapy Medicinal Products Market (2026 - 2033)

Advanced Therapy Medicinal Products Market Summary

The global advanced therapy medicinal products market size was valued at USD 42.2 billion in 2025 and is projected to grow from USD 49.3 billion in 2026 to USD 139.6 billion in 2033, at a CAGR of 16.0% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 42.5% in 2025. The success of products such as Kymriah, Zolgensma, and others is the key factor driving the market.

The emergence of Advanced Therapy Medicinal Products (ATMPs) has transformed the pharmaceutical industry and disease treatment landscape. It has opened new avenues for treating incurable diseases and several cancer types. A growing number of Mesenchymal Stromal/Stem Cell (MSC)- based clinical trials have been registered recently as a new treatment paradigm for SARS-CoV-2 infection. These therapies have shown promising results as treatment modalities in research programs, further supplementing the market's organic revenue growth.

Although the market for advanced therapy medicinal products is currently in its nascent stage, it is continuously growing. Conventional drug manufacturers seeking a competitive edge are considering ATMPs as a lucrative source of revenue in future healthcare systems. Currently, this arena is very active, and companies are investing significantly in clinical trials of ATMPs post the success of approved products.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

Regulatory agencies such as the FDA and EMA offer expedited approval pathways, orphan drug designations, and regenerative medicine advanced therapy (RMAT) designations to support ATMP development. Governments and public-private partnerships are also increasing funding for research and infrastructure in advanced therapy. This supportive regulatory environment shortens time-to-market and encourages innovation. It also boosts investor confidence in the sector.

Market Dynamics

Analyst Perspective

The advanced medicinal products market is driven by the rising prevalence of chronic diseases. Growing demand for personalized and targeted therapies supports market growth. Advances in biotechnology, cell therapy, and gene therapy are accelerating innovation. Increased R&D investments and faster regulatory approvals further boost development. Precision medicine is improving treatment outcomes and reducing side effects. AI and bioinformatics are enhancing drug discovery and innovation. High costs, complex manufacturing, and strict regulations remain key challenges. Despite these barriers, increasing healthcare spending and unmet medical needs continue to drive market growth.

Therapy Type Insights

The tissue-engineered product segment accounted for the largest revenue share of around 40.0% in 2025. The segment's growth stems from the growing use of tissue engineering in modern medical treatment and regenerative healthcare. This focus is particularly evident in restoring the function of damaged or diseased tissues and organs. The segment has gained significant momentum in recent years. This is clear from the rising number of scientific publications, clinical studies, and research initiatives aimed at developing advanced tissue-based therapies. In addition, ongoing improvements in biomaterials, scaffold design, and 3D bioprinting are making tissue-engineered solutions more effective and scalable. The growing use of these products for applications like wound healing, orthopedic reconstruction, and reconstructive surgeries is boosting demand. This trend supports continued growth in the segment over the forecast period.

The cell therapy segment is expected to witness the fastest CAGR during the forecast period. This increase is mainly due to the rising global use of CAR-T therapies as a groundbreaking treatment for blood cancers. Major biopharmaceutical companies such as Novartis AG, Gilead Sciences, Inc., and Bristol Myers Squibb are actively expanding their CAR-T therapy portfolios and global reach through ongoing clinical advancements and strategic partnerships. CAR-T therapy is a personalized immunotherapy. In this process, doctors take a patient’s T-cells and modify them in a lab so they can target and destroy cancer cells. After this, they put the modified cells back into the patient to help fight the disease. For instance, in January 2026, Cipla Limited, through its subsidiary Medpro Pharmaceutica, signed an exclusive licensing and supply agreement with ImmunoACT. This deal allows them to sell talicabtagene autoleucel, India’s first locally developed CAR-T cell therapy, in Algeria, South Africa, and Morocco. This autologous anti-CD19 therapy is approved for relapsed or refractory B-cell Non-Hodgkin’s Lymphoma and B-cell Acute Lymphoblastic Leukemia. It has shown strong effectiveness, lasting responses, and a good safety record in over 500 patients treated in India.

Regional Insights

North America dominated the advanced therapy medicinal products industry, accounting for the largest revenue share of around 42.5% in 2025. The growing number of clinical trials for this new treatment modality in the U.S. supports regional growth. Also, favorable regulatory environments across various countries have introduced frameworks and guidelines to facilitate the development and commercialization of ATMPs. These regulations aim to streamline the approval process, ensure patient safety, and encourage investment and innovation in the field. For instance, in April 2026, Novartis announced plans to expand its U.S. manufacturing and research and development presence with a new facility in Morrisville, North Carolina. This site will focus on producing active pharmaceutical ingredients (API) for solid dosage forms and RNA therapeutics. This investment improves its domestic manufacturing capabilities, from active ingredients to finished medicines. The company is also increasing capacity across various technology platforms, including small molecules, large molecules, radioligand therapies, and newer methods like cell and gene therapies. 

To learn more about this report, Download Free Sample Report

Asia Pacific Advanced Therapy Medicinal Products Market Trends

The advanced therapy medicinal products market in the Asia Pacific is expected to grow at the fastest CAGR during the forecast period. The regional market is growing rapidly due to higher healthcare spending and increased investment in research and development focused on advanced biologics and regenerative medicines. This rise in funding has sped up the creation of new therapies and technologies, boosting growth in the region. There is also notable progress in gene editing, stem cell research, and genetic engineering. This progress is backed by collaboration among academic institutions, research organizations, and industry participants. These partnerships foster quick innovation and improve the clinical application of ATMPs. According to HiTech Health’s 2025 ATMP Sector Review, Asia Pacific has overtaken North America in the number of ATMP clinical trials for the first time, with about 990 ongoing trials in the region, including 716 in China. In North America, there are 916 trials, with 890 taking place in the United States. This increase in clinical trial activity shows Asia Pacific’s growing role as a global center for ATMP development, significantly boosting regional market growth.

Key Advanced Therapy Medicinal Products Company Insights

The market for advanced therapy medicinal products has witnessed tremendous growth in the past few years. The increasing number of companies entering this arena is expected to intensify market competition. Besides, recent approvals of ATMPs have accelerated the expansion in this area. Market players are implementing various strategies to sustain their market positions. Collaborations with contract manufacturing organizations are the current trend observed in this space. The CDMO/CMOs are witnessing high demand for their services owing to increasing R&D activity in this market.

• In June 2025, AbbVie and Capstan Therapeutics announced a deal in which AbbVie will acquire Capstan Therapeutics, a clinical-stage biotechnology company focused on improving in vivo cell engineering through RNA delivery with lipid nanoparticle (tLNP) technology. This acquisition includes CPTX2309, a potential first-in-class in vivo tLNP-based anti-CD19 CAR-T therapy currently in Phase 1 development for B-cell-mediated autoimmune diseases. As part of the agreement, AbbVie will also receive Capstan’s unique tLNP platform, designed to deliver RNA payloads, including mRNA, enabling targeted in vivo engineering of specific cell types.

• In April 2026, the U.S. Food and Drug Administration (FDA) granted full approval to Kite’s CAR T-cell therapy, Tecartus (brexucabtagene autoleucel), for adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). This approval includes data on effectiveness, safety, and the drug's pharmacokinetics from Cohort 3 of the ZUMA-2 study. This study involved patients who are R/R after one or more lines of therapy and who have not received Bruton tyrosine kinase inhibitors (BTKis).

Key Advanced Therapy Medicinal Products Companies:

The following key companies have been profiled for this study on the advanced therapy medicinal products market. 

• Spark Therapeutics, Inc.

• Bluebird Bio, Inc.

• Novartis AG

• UniQure N.V.

• Celgene Corporation

• Gilead Lifesciences, Inc.

• Kolon TissueGene, Inc.

• JCR Pharmaceuticals Co., Ltd.

• MEDIPOST

• Vericel Corporation

• PHARMICELL Co., Ltd

• Organogenesis Inc.

Global Advanced Therapy Medicinal Products Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global advanced therapy medicinal products market report based on therapy type, and region:

To learn more about this report, Download Free Sample Report

• Therapy Type Outlook (Revenue, USD Billion, 2021 - 2033)

  • Cell Therapy

    • Stem Cell Therapy

    • Non-stem Cell Therapy

  • Gene Therapy

  • Tissue Engineered Product

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Norway

    • Denmark

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • Saudi Arabia

    • South Africa

    • UAE

    • Kuwait